Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. Bossi A, et al. Among authors: fizazi k. Lancet. 2024 Nov 23;404(10467):2065-2076. doi: 10.1016/S0140-6736(24)01865-8. Lancet. 2024. PMID: 39580202 Clinical Trial.
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
Fléchon A, Fizazi K, Gourgou-Bourgade S, Théodore C, Beuzeboc P, Geoffrois L, Mottet N, Chevreau C, Culine S. Fléchon A, et al. Among authors: fizazi k. Anticancer Drugs. 2006 Jul;17(6):705-8. doi: 10.1097/01.cad.0000210337.85526.cc. Anticancer Drugs. 2006. PMID: 16917216
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.
Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M, Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fossa SD, Fromont G. Fizazi K, et al. Ann Oncol. 2008 Feb;19(2):259-64. doi: 10.1093/annonc/mdm472. Epub 2007 Nov 27. Ann Oncol. 2008. PMID: 18042838 Free article.
The postchemotherapy PSA surge syndrome.
Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. Thuret R, et al. Among authors: fizazi k. Ann Oncol. 2008 Jul;19(7):1308-1311. doi: 10.1093/annonc/mdn062. Epub 2008 Mar 19. Ann Oncol. 2008. PMID: 18356135 Free article.
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Theodore C, Chevreau C, Yataqhene Y, Fizazi K, Delord JP, Lotz JP, Geoffrois L, Kerbrat P, Bui V, Flechon A. Theodore C, et al. Among authors: fizazi k. Ann Oncol. 2008 Aug;19(8):1465-1469. doi: 10.1093/annonc/mdn122. Epub 2008 Apr 2. Ann Oncol. 2008. PMID: 18385203 Free article. Clinical Trial.
541 results